Figure 5 of Noh, Mol Vis 2015; 21:1191-1200.


Figure 5. TGF-β1 and TGF-β2 protein evaluated with ELISA (continuous 48 h) in serum-free condition. A: Human Tenon’s fibroblasts (HTFs) treated with the 0.5 mg/ml ranibizumab concentration demonstrated significant increase in transforming growth factor- β 1 (TGF-β1) levels compared to the control antibody (p<0.01; n=3). B: HTFs treated with the 0.5 mg/ml ranibizumab concentration for 48 h in serum-free conditions demonstrated a significant increase in the TGF-β2 levels compared to the control antibody (p<0.05; n=3).